派安普利单抗联合化疗治疗转移性或局部晚期鳞状非小细胞肺癌的近期疗效和毒副反应  

Short-term efficacy and toxicities of penpulimab combined with chemotherapy in the treatment of metastatic or locally advanced squamous non-small cell lung cancer

作　　者：梁艳[1] 姜溪[1] 武永存[1] 楚丽[1] 段颖欣 王力军[1] LIANG Yan;JIANG Xi;WU Yongcun;CHU Li;DUAN Yingxin;WANG Lijun(Department of Radiotherapy and Chemotherapy,the Second Affiliated Hospital of Xingtai Medical College,Xingtai,054000,Hebei,China)

机构地区：[1]邢台医学高等专科学校第二附属医院放化疗科,河北邢台054000

出　　处：《肿瘤药学》2024年第5期595-601,共7页Anti-Tumor Pharmacy

基　　金：邢台市科技局重点研发计划项目(2021ZC172)。

摘　　要：目的探讨派安普利单抗联合化疗治疗转移性或局部晚期鳞状非小细胞肺癌(NSCLC)的近期疗效和毒副反应。方法纳入2021年10月—2022年8月本院收治的转移性/局部晚期鳞状NSCLC患者作为研究对象,随机抽签法分为两组,各62例。对照组接受化疗治疗,观察组在对照组基础上联合派安普利单抗治疗。比较两组患者的近期疗效,治疗前后免疫功能指标、肺癌相关肿瘤标志物水平及生存期差异,并统计两组患者毒副反应发生情况。结果观察组中1例完全缓解(CR),32例部分缓解(PR),客观缓解率(ORR)率为53.22%;对照组23例PR,ORR率为37.10%,观察组患者1~2级反应性毛细血管增殖症发生率和甲状腺减退发生率均明显高于对照组(P<0.05)。观察组治疗后免疫功能指标(CD3+、CD4+、CD8+、CD4+/CD8+)和血清肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、癌胚抗原(CEA)及血管内皮生长因子(VEGF)]水平改善效果均明显优于对照组(P<0.05)。所有患者随访2年,未出现失访患者。观察组患者总生存期(OS)[(20.41±0.25)个月]和无进展生存期(PFS)[(18.84±0.46)个月]均显著长于对照组(P<0.05)。结论派安普利单抗联合化疗可延长转移性/局部晚期鳞状NSCLC患者的生存期,改善免疫功能,下调血清肿瘤标志物水平。Objective To investigate the short-term efficacy and toxicity of penpulimab combined with chemotherapy in the treatment of metastatic or locally advanced squamous non-small cell lung cancer(NSCLC).Methods The study includ-ed patients with metastatic/locally advanced squamous NSCLC and admitted to our hospital between October 2021 and Au-gust 2022.These patients were randomly assigned into two groups,each containing 62 cases.Patients in control group re-ceived chemotherapy,while those in observation group received chemotherapy combined with penpulimab.Compare the short-term efficacy,immune factors before and after treatment,levels of lung cancer-related tumor markers,and survival time between the two groups,as well as the occurrence of adverse reactions in both groups.Results In the observation group,there was 1 case of complete response(CR)and 32 cases of partial response(PR),resulting in an overall response rate(ORR)of 53.22%.In the control group,there were only 23 cases of PR,with an ORR of 37.10%.The incidence of reac-tive capillary proliferation and hypothyroidism was significantly higher in the observation group than in the control group(P<0.05).The post-treatment immune function indicators(CD3+,CD4+,CD4+/CD8+,CD8+)and tumor marker levels(CYFRA21-1,CEA,and VEGF)were improved much more in the observation group than in the control group(all P<0.05).All patients were followed for 2 years,and no patients were lost in the follow-up.The OS[(20.41±0.25)months]and PFS[(18.84±0.46)months]of patients in the observation group were both longer than in the control group(P<0.05).Conclusion Penpulimab combined with chemotherapy can prolong the survival time of metastatic/locally advanced squa-mous NSCLC patients,improve their immune function and down-regulate their levels of tumor markers.

关 键 词：鳞状非小细胞肺癌 转移性 局部晚期 派安普利单抗 化疗 毒副反应 

分 类 号：R734.2[医药卫生—肿瘤]